This database provides information about AIDS vaccine candidates, including their design, composition, and manufacturer, as well as information about trials evaluating AIDS vaccine candidates in human volunteers.
Please note that many AIDS vaccine candidates have been tested in multiple trials. Also, a single clinical trial may test multiple vaccine candidates, either to assess the effects of administering two vaccine candidates sequentially (the so-called prime-boost strategy) or to compare individual vaccine candidates.
In this database, variations in composition of different vaccine candidates (those that have different inserts) are classified separately. For example, the company VaxGen conducted Phase III trials on two different mixtures of the outer envelope protein from HIV, each based on different subtypes (genetic variant) of the virus; these are classified separately in the database.
The database includes vaccine candidates that are being, or were ever, tested in human volunteers. Information on candidates that are still being developed in the laboratory are not included, even if a clinical trial is being considered or in planning. New clinical trials are only added to the database once they are considered officially open by the trial organizers.
Trials are identified by the current stage of the study, for example, whether they are ongoing or completed. This categorization is obtained from either the sources described below or from the trial organizer. Many organizers have different ways of classifying when a trial is actually considered complete. For the purposes of this database, we rely on the information provided by the organizations involved in the trial.
IAVI Report relies on numerous sources to collect the information in the database and is incredibly grateful to the organizations and individuals involved in clinical trials of AIDS vaccine candidates for providing and regularly updating the entries, helping to keep this valuable resource up to date.
For more information:
If you can provide additional information or have any corrections to content already included, we greatly appreciate any feedback. Please contact us with any questions, comments, or corrections at iavireport@iavi.org.
Sources:
Most of the information on US-based trials was obtained from the US National Institutes of Health (NIH), NIH publications of clinical trials, and clinicaltrials.gov.
Trial information was also obtained from the HIV Vaccine Trials Network (HVTN). Special thanks also to Barney Graham of the Vaccine Research Center (VRC), who maintains a list of vaccine trials. The VRC is part of the National Institute of Allergy and Infectious Diseases (NIAID) at the NIH.
Many other individual investigators and clinical teams have provided essential information to the database. Our thanks, in particular, to: Mary Enama (VRC), Rona Siskind (Division of AIDS or DAIDS/NIAID), Dale Lawrence (DAIDS/NIAID), Taiwo Olamide (DAIDS/NIAID, consultant, Henry M. Jackson Foundation), Anne de Saunière and Dr. Jean-Paul Levy (L'Agence Nationale de Recherches sur le SIDA, the French National Agency for AIDS Research), Song Ding (EuroVacc Foundation), Carter Bentley (HVTN), Eric Sandström (Karolinska Institute), Patricia Flynn and Karen Slobod (St. Jude Children's Research Hospital), Lisa Reilly and Sarah Fitzsimmons (US Military HIV Research Program, Henry M. Jackson Foundation), Tom Cole and David Lewis (St. George's, University of London), Rebekah Puls and Sean Emery (National Centre in HIV Epidemiology and Clinical Research, University of New South Wales), Edward Karamov (Institute of Immunology, Moscow), Peter Anton (Center for HIV Prevention Research, University of California in Los Angeles AIDS Institute), Elke Jordan (Bavarian Nordic), Carlos Duarte Cano (Cuba), Raphaelle El Habib (Aventis-Pasteur), Thomas Evans (University of Rochester and AVEG/HIVNET investigator), J. G. Guillet, Kelley Lennon, Sheena McCormack, Julie McElrath (University of Washington and HVTN), Alice Melkonian, and Merlin Robb (Walter Reed Army Institute of Research).